

Eisai's Slavery and Human Trafficking Statement

INTRODUCTION FROM THE CHAIRMAN & CEO, EISAI EMEA

Eisai is committed to preventing slavery and human trafficking in its organisation and supply chains. In 2015, new legislation (the Modern Slavery Act 2015) came into force in the UK, which seeks to combat slavery, servitude, forced or compulsory labour and human trafficking. As a company, we acknowledge our responsibilities under the Modern Slavery Act 2015 and are taking measures to ensure that there is no scope for modern slavery to be present in any part of our organisation or supply chains.

EISAI'S STRUCTURE

Eisai is one of the world's leading research-based pharmaceutical companies, with its parent company, Eisai Co., Ltd., based in Tokyo, Japan.

Eisai Europe Limited is the UK-based subsidiary of Eisai Co., Ltd. and is responsible for Eisai's operations in the EMEA region (comprising Europe, Middle East, Africa, Oceania, Russia and the Commonwealth of Independent States). Eisai Europe Limited has two UK subsidiaries: Eisai Limited, which is responsible for Eisai's commercial operations in the UK, and Eisai Manufacturing Limited, which carries out manufacturing and packaging activities for Eisai's global business.

In the period 1 April 2015 to 31 March 2016, the global annual turnover of the Eisai Group was 547.9 billion Japanese Yen.

OUR UK BUSINESS

Our UK business is organised into two principal product-related business groups: the Oncology Business Group and the Neurology Business Group, which comprise both research and development activities and commercial operations. A further business group, the Established Product Partner Markets Business Group, is responsible for the commercial operations of other Eisai products and for the activities of Eisai's local distributors. Manufacturing activities are also undertaken in the UK by Eisai Manufacturing Limited

OUR SUPPLY CHAINS

Our supply chains include the manufacture and supply of active pharmaceutical ingredients and excipients for pharmaceutical products, the manufacture and packaging of semi-finished and finished pharmaceutical products, and the promotion, sale and distribution of finished pharmaceutical products

OUR PRESENT AND FUTURE COMMITMENT TO PREVENTING SLAVERY AND HUMAN TRAFFICKING


We are committed to ensuring that there is no modern slavery or human trafficking in any part of our business, including our supply chains.

Our internal global Charter of Business Conduct and Compliance Code of Conduct reflect our commitment to acting ethically and with integrity in all our business relationships, and our Compliance teams run regular awareness programmes and operate an internal speak-up procedure to encourage Compliance within our business.

We are working to implement an external Supplier Code of Business Ethics which will reinforce our requirement for all suppliers to Eisai to apply equivalent ethics and integrity to their own operations.

We are also taking steps to conduct a review of our global operations to identify and assess any potential risk areas in our supply chains, where we can take further preventative action to help ensure that slavery and human trafficking does not occur in any of our supply chains.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes the Eisai group's slavery and human trafficking statement for the financial year ending 31 March 2016.

A handwritten signature in black ink, consisting of a large, stylized initial 'G' followed by a horizontal line and a complex, scribbled end.

Gary Hendler
Chairman & CEO, Eisai EMEA
Director, Eisai Europe Limited, Eisai Limited and Eisai Manufacturing Limited

22 September 2016